Fig. 3: Overall survival from the time of therapy initial until death or last known alive, among patients treated with DNMTI therapy. | Blood Cancer Journal

Fig. 3: Overall survival from the time of therapy initial until death or last known alive, among patients treated with DNMTI therapy.

From: Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)

Fig. 3

Survival is shown according to the best overall response on DNMTI therapy (IWG 2006 criteria) but including patients who met CRh and reclassifying them from patients who met mCR or SD. Median OS was similar between CR (23.3mo) and CRh (25mo). This was longer than patients whose best response remained classified as mCR (17.2mo), SD (16.3mo), and PD (8.7mo) (p < 0.001).

Back to article page